Efficacy and safety of triple therapy with recombinant interleukin-1β, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, the non-responders to previous treatment with interferon and ribavirin

To assess the efficacy and safety of an experimental course of antiviral therapy with recombinant IL-1β in combination with recombinant interferon-α2b and ribavirin in patients with chronic hepatitis C infected with genotype 1 hepatitis C virus in lacking the virologic response to previous dual therapy pegIFN-α or standard IFN-α and ribavirin has been formed by a group of 50 patients. All patients were treated with recombinant IL-1β – 10 subcutaneous injection at a dose of 0.005 mg/kg every other day, the course of 3 weeks, with 5 courses, recombinant IFN-α2b – subcutaneous injections of 3 million IU every other day for 48 weeks. Ribavirin 1000–1200 mg per day (depending on body weight) for 48 weeks. The duration of follow-up after the end of therapy was 24 weeks. Estimated sustained virologic response (SVR). Comparison of SVR according to the version of virologic response in primary treatment showed that the use of the pilot treatment scheme is most effective at relapse (63%) than in the «null-responders» (33%) and partial (23%) responses to the preceding treatment. In the present study did not reveal a single case of serious adverse events or unexpected adverse events. Thus, the inclusion of proven safety of recombinant IL-1β in the scheme of antiviral therapy in combination with standard interferon-α and ribavirin in patients with chronic hepatitis C, and demonstrated the effectiveness of using recombinant IL-1β (in combination with standard interferon-α and ribavirin), especially in patients with recurrent HCV-infection.

chronic viral hepatitis C, antiviral therapy, efficacy, safety, interferon, IL-1β

1. Manns, M.P. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. / M.P. Manns [et al.] // Lancet. – 2001. – V. 358. – P. 958–965.

2. Fried, M.W. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection / M.W. Fried [et al.] // N. Engl. J. Med. – 2002. – V. 347. – P. 975–982.

3. Hadziyannis, S.J. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose / S.J. Hadziyannis [et al.] // Ann. Intern. Med. – 2004. – V. 140. – P. 346–355.

4. Жданов, К.В. Эволюция противовирусной терапии хронических вирусных гепатитов В, С, D / К.В. Жданов, К.В. Козлов, В.С. Сукачев // Журнал инфектологии. – 2009. – Т. 1, № 4. – С. 23–35.

5. Jacobson I.M., McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection / I.M. Jacobson [et al.] // N. Engl. J. Med. – 2011. – V. 364, № 25. – Р. 2405–2416

6. Sherman, K.E. Response-guided telaprevir combination treatment for hepatitis C virus infection./ K.E. Sherman [et al.] // N. Engl. J. Med. – 2011. – V. 365, № 11. – P. 1014–1024.

7. Poordad, F. Boceprevir for untreated chronic HCV genotype 1 infection / F. Poordad [et al.] // N. Engl. J. Med. – 2011. – V. 364, № 13. – Р. 1195–1206

8. Жданов, К.В. Вирусные гепатиты / К.В. Жданов [и др.]. – СПб.: Фолиант, 2011. – 304 с.

9. Zeuzem, S. Telaprevir for retreatment of HCV infection. / S. Zeuzem [et al.] // N. Engl. J. Med. – 2011. – V. 364, № 25. – P. 2417–2428.

10. Bacon, B.R. Boceprevir for previously treated chronic HCV genotype 1 infection / B.R. Bacon [et al.] // N. Engl. J. Med. – 2011. – V. 364, № 13. – P. 1207–1217.

11. Bronowicki, J.P. Sustained Virologic Response (SVR) in Prior PegInterferon/Ribavirin (PR) Treatment Failures After Retreatment with Boceprevir (BOC) + PR: PROVIDE Study Interim Results / J.P. Bronowicki [et al.] // J. of Hep. – 2012. – V. 56, suppl. 2. – P. S6.

12. Кузнецов, Н.И. Результаты использования рекомбинантных препаратов интерлейкина-1 бета и интерферона альфа-2b в терапии больных хроническим вирусным гепатитом С / Н.И. Кузнецов [и др.] // Клинические перспективы гастроэнтерологии, гепатологии. – 2006. – № 5. – С. 8–14.

13. Симбирцев, А.С. Биология семейства интерлейкина-1 человека / А.С. Симбирцев // Иммунология. – 1998. – № 3. – С. 9–17.

14. Симбирцев, А.С. Интерлейкин-1: от эксперимента в клинику / А.С. Симбирцев // Медицинская иммунология. – 2001. – Т. 3, № 3. – С. 431–438.

15. Duong. Hepatitis C Virus Inhibits Jak-STAT Signaling Through Up-regulation of Protein Phosphatase 2A. / Duong [et al.] // Gastroenterology. – 2004. – V.126, № 1. – P. 263–277.

16. Zhu, H. Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway / H. Zhu, C. Liu // J. Virology. – 2003. – V.77. – P. 5493–5498.

17. Jensen, D. Pegylated interferon alfa-2a (40KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12KD)/RBV: final efficacy and safety outcomes of the REPEAT study / D. Jensen // Ann. Intern. Med. – 2009. – V. 150. – P. 528–540.

18. Leevy, C.B. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin / C.B. Leevy // Dig Dis Sci. – 2008. – V. 53, № 7. – Р. 1961–1996.